Cited by 406Cancer Immunotherapy and BiomarkersTGF-β signaling in diseasesImmunotherapy and Immune Responses

The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Open access

Strauss, Julius, Heery, Christopher R., Schlom, Jeffrey, Madan, Ravi A., Cao, Liang, Kang, Zhigang, Lamping, Elizabeth, Marté, Jennifer L., Donahue, Renee N., Grenga, Italia, Cordes, Lisa, Christensen, Olaf, Mahnke, Lisa, Helwig, Christoph, Gulley, James L.·2018·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-17-2653PMC PMC7985967

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Purpose: M7824 (MSB0011359C) is an innovative first-in-class bifunctional fusion protein composed of a mAb against programmed death ligand 1 (PD-L1) fused to a TGFβ “trap.” Experimental Design: In the 3+3 dose-escalation component of this phase I study (NCT02517398), eligible patients with advanced solid tumors received M7824 at 1, 3, 10, or 20 mg/kg once every 2 weeks until confirmed progression, unacceptable toxicity, or trial withdrawal; in addition, a cohort received an initial 0.3 mg/kg dose to evaluate pharmacokinetics/pharmacodynamics, followed by 10 mg/kg dosing. The primary objective is to determine the safety and maximum tolerated dose (MTD); secondary objectives include pharmacokinetics, immunogenicity, and best overall response. Results: Nineteen heavily pretreated patients with ECOG 0–1 have received M7824. Grade ≥3 treatment-related adverse events occurred in four patients (skin infection secondary to localized bullous pemphigoid, asymptomatic lipase increase, colitis with associated anemia, and gastroparesis with hypokalemia). The MTD was not reached. M7824 saturated peripheral PD-L1 and sequestered any released plasma TGFβ1, -β2, and -β3 throughout the dosing period at >1 mg/kg. There were signs of efficacy across all dose levels, including one ongoing confirmed complete response (cervical cancer), two durable confirmed partial responses (PR; pancreatic cancer; anal cancer), one near-PR (cervical cancer), and two cases of prolonged stable disease in patients with growing disease at study entry (pancreatic cancer; carcinoid). Conclusions: M7824 has a manageable safety profile in patients with heavily pretreated advanced solid tumors. Early signs of efficacy are encouraging, and multiple expansion cohorts are ongoing in a range of tumors. Clin Cancer Res; 24(6); 1287–95. ©2018 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-2653

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,725

Show all 35 references

Sorted by citations

Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,826
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Togashi, Y., Shitara, K., & Nishikawa, H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0175-7 · Cited by 1,620
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
TGF-β signaling in health, disease and therapeutics
Deng, Z., Fan, T. T., Chu, X., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,360
Targeting TGF-β signal transduction for fibrosis and cancer therapy
Peng, D., Fu, M., Wang, M., Wei, Y., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01569-x · Cited by 1,151
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Marin-Acevedo, J. A., Dholaria, B., Soyano, A. E., Knutson, K. L., Chumsri, S., & Lou, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0582-8 · Cited by 819
Combination strategies to maximize the benefits of cancer immunotherapy
Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01164-5 · Cited by 654
Cancer-associated fibroblasts: from basic science to anticancer therapy
Yang, D., Liu, J., Qian, H., & Zhuang, Q. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01013-0 · Cited by 572
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 528
Novel therapies emerging in oncology to target the TGF‐β pathway
Kim, B.-G., Malek, E., Choi, S. H., Ignatz-Hoover, J. J., & Driscoll, J. J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01053-x · Cited by 453
Genomic correlates of response to immune checkpoint blockade
Keenan, T. E., Burke, K. P., & Van Allen, E. M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0382-x · Cited by 448
Targeting TGFβ signal transduction for cancer therapy
Liu, S., Ren, J., & ten Dijke, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00436-9 · Cited by 413
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 454
Overcoming TGFβ-mediated immune evasion in cancer
Tauriello, D. V. F., Sancho, E., & Batlle, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00413-6 · Cited by 377
Tumor Immune Microenvironment during Epithelial–Mesenchymal Transition
Taki, M., Abiko, K., Ukita, M., Murakami, R., Yamanoi, K., Yamaguchi, K. D., Hamanishi, J., Baba, T., Matsumura, N., & Mandai, M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4459 · Cited by 368
Molecular therapies for HCC: Looking outside the box
Faivre, S. J., Rimassa, L., & Finn, R. S. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.010 · Cited by 332
Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion
Jiang, Y., & Zhan, H. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.10.013 · Cited by 319
Biomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma
Montal, R., Sia, D., Montironi, C., Leow, W. Q., Esteban-Fabró, R., Pinyol, R., Torres‐Martín, M., Bassaganyas, L., Moeini, A., Peix, J., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.008 · Cited by 309
Immuno-Oncology: Emerging Targets and Combination Therapies
Marshall, H. T., & Djamgoz, M. B. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00315 · Cited by 303
TGF ‐β as a driver of fibrosis: physiological roles and therapeutic opportunities
Budi, E. H., Schaub, J. R., Decaris, M. L., Turner, S., & Derynck, R. (2021) · The Journal of Pathology · doi:10.1002/path.5680 · Cited by 310
Cancer‐associated fibroblasts in breast cancer: Challenges and opportunities
Hu, D., Li, Z., Zheng, B., Lin, X., Pan, Y., Gong, P., Zhuo, W., Hu, Y., Chen, C., Chen, L., et al. (2022) · 癌症：英文版 · doi:10.1002/cac2.12291 · Cited by 310
Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
Lee, J., Shklovskaya, E., Lim, S. Y., Carlino, M. S., Menzies, A. M., Stewart, A., Pedersen, B., Irvine, M., Alavi, S., Yang, J. Y. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15726-7 · Cited by 300
Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives
Fang, Z., Meng, Q., Xu, J., Wang, W., Zhang, B., Liu, J., Liang, C., Hua, J., Zhao, Y., Yu, X., et al. (2022) · 癌症：英文版 · doi:10.1002/cac2.12392 · Cited by 304
Clinical development of therapies targeting TGFβ: current knowledge and future perspectives
Ciardiello, D., Élez, E., Tabernero, J. M., & Seoane, J. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.009 · Cited by 279
Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
Lind, H., Gameiro, S. R., Jochems, C., Donahue, R. N., Strauss, J., Gulley, J. L., Palena, C., & Schlom, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000433 · Cited by 247
Self-citation
Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future
Christenson, E. S., Jaffee, E. M., & Azad, N. S. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30795-8 · Cited by 245
The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives
Majidpoor, J., & Mortezaee, K. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108707 · Cited by 236
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
Yi, M., Zhang, J., Li, A., Niu, M., Yan, Y., Jiao, Y., Luo, S., Zhou, P., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01045-x · Cited by 233
Exploiting innate immunity for cancer immunotherapy
Yi, M., Li, T., Niu, M., Mei, Q., Zhao, B., Chu, Q., Dai, Z., & Wu, K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01885-w · Cited by 250
Immune checkpoint inhibitors: The linchpins of modern immunotherapy
Wilky, B. A. (2019) · Immunological Reviews · doi:10.1111/imr.12766 · Cited by 214
If we build it they will come: targeting the immune response to breast cancer
Gatti-Mays, M. E., Balko, J. M., Gameiro, S. R., Bear, H. D., Prabhakaran, S., Fukui, J. A., Disis, M. L., Nanda, R., Gulley, J. L., Kalinsky, K. M., et al. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0133-7 · Cited by 210
Self-citation
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial
Paz-Ares, L. G., Kim, T. M., Vicente, D., Felip, E., Lee, D. H., Lee, K. H., Lin, C., Flor, M. J., Nicola, M. D., Alvarez, R. M., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.003 · Cited by 208
Self-citation
Overview of current targeted therapy in gallbladder cancer
Song, X., Hu, Y., Li, Y., Shao, R., Liu, F., & Liu, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00324-2 · Cited by 208
M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine
Knudson, K. M., Hicks, K. C., Luo, X., Chen, J.-Q., Schlom, J., & Gameiro, S. R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1426519 · Cited by 195
Self-citation
Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study
Kamath, S. D., Kalyan, A., Kircher, S. M., Nimeiri, H. S., Fought, A. J., Benson, A. B., & Mulcahy, M. F. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0473 · Cited by 200
Trial watch: IDO inhibitors in cancer therapy
Naour, J. L., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777625 · Cited by 195
A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
David, J. M., Dominguez, C., McCampbell, K. K., Gulley, J. L., Schlom, J., & Palena, C. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1349589 · Cited by 180
Self-citation
Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics
Davda, J. P., Declerck, P. J., Hu‐Lieskovan, S., Hickling, T. P., Jacobs, I. A., Chou, J., Salek‐Ardakani, S., & Kraynov, E. A. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0586-0 · Cited by 181
Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment
Gulley, J. L., Schlom, J., Barcellos‐Hoff, M. H., Wang, X., Seoane, J., Audhuy, F., Lan, Y., Dussault, I., & Moustakas, A. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13146 · Cited by 182
Self-citation
Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect
Nishiga, Y., Drainas, A. P., Baron, M., Bhattacharya, D., Barkal, A. A., Ahrari, Y., Mancusi, R. A., Ross, J., Takahashi, N., Thomas, A., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00456-0 · Cited by 180
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01363-8 · Cited by 184
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
Strauss, J., Gatti-Mays, M. E., Cho, B. C., Hill, A., Salas, S., McClay, E. F., Redman, J. M., Sater, H. A., Donahue, R. N., Jochéms, C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001395 · Cited by 153
Self-citation
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
Yoo, C., Oh, D. Y., Choi, H. J., Kudo, M., Ueno, M., Kondo, S., Chen, L.-T., Osada, M., Helwig, C., Dussault, I., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000564 · Cited by 155
Self-citation
Impairment of NKG2D-Mediated Tumor Immunity by TGF-β
Lazarova, M., & Steinle, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02689 · Cited by 149
Transforming Growth Factor-β: A Multifunctional Regulator of Cancer Immunity
Xue, V. W., Chung, J. Y., Córdoba, C. A. G., Cheung, A. H. K., Kang, W., Lam, E. W. ‐., Leung, K. T., To, K., Lan, H. Y., & Tang, P. M. (2020) · Cancers · doi:10.3390/cancers12113099 · Cited by 154
Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer
Stüber, T. N., Monjezi, R., Wallstabe, L., Kühnemundt, J., Nietzer, S., Dandekar, G., Wöckel, A., Einsele, H., Wischhusen, J., & Hudecek, M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000676 · Cited by 151
Tumor Plasticity and Resistance to Immunotherapy
Horn, L. A., Fousek, K., & Palena, C. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.02.001 · Cited by 148
Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies
Jacquelot, N., Tellier, J., Nutt, S. L., & Belz, G. T. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1900508 · Cited by 144
Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy
Kim, J.-H., Kim, B. S., & Lee, S. (2020) · Immune Network · doi:10.4110/in.2020.20.e4 · Cited by 147
TGFβ control of immune responses in cancer: a holistic immuno-oncology perspective
Nixon, B. G., Gao, S., Wang, X., & Li, M. O. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00796-z · Cited by 144
Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?
Ben‐Shmuel, A., Biber, G., & Barda‐Saad, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00275 · Cited by 138
Cytokine and Chemokine Signals of T‐Cell Exclusion in Tumors
Zhang, Y., Guan, X.-Y., & Jiang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594609 · Cited by 133
Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
Shen, X., Zhang, L., Li, J., Li, Y., Wang, Y., & Xu, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01337 · Cited by 133
Immune Checkpoint Inhibitors in the Treatment of HCC
Donisi, C., Puzzoni, M., Ziranu, P., Lai, E., Mariani, S., Saba, G., Impera, V., Dubois, M., Persano, M., Migliari, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.601240 · Cited by 133
Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1–mediated tumor eradication
Horn, L. A., Chariou, P. L., Gameiro, S. R., Qin, H., Iida, M., Fousek, K., Meyer, T. J., Cam, M. C., Flies, D. B., Langermann, S., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci155148 · Cited by 134
Self-citation
Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer
Saux, O. L., Ray-Coquard, I. L., & Labidi‐Galy, S. I. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.017 · Cited by 127
Cancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment
Ganguly, D., Chandra, R., Karalis, J. D., Teke, M. E., Aguilera, T. A., Maddipati, R., Wachsmann, M., Ghersi, D., Siravegna, G., Zeh, H. J., et al. (2020) · Cancers · doi:10.3390/cancers12092652 · Cited by 130
Stromal fibroblasts mediate anti-PD-1 resistance via MMP-9 and dictate TGFβ inhibitor sequencing in melanoma
Zhao, F., Evans, K., Xiao, C., DeVito, N., Theivanthiran, B., Holtzhausen, A., Siska, P. J., Blobe, G. C., & Hanks, B. A. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0086 · Cited by 117
Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy
Principe, D. R., Narbutis, M., Kumar, S., Park, A. J., Viswakarma, N., Dorman, M. J., Kamath, S. D., Grippo, P. J., Fishel, M. L., Hwang, R. F., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2959 · Cited by 130
Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing
Li, Z., Song, W., Rubinstein, M. P., & Liu, D. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0684-3 · Cited by 124
Recruitment and Expansion of Tregs Cells in the Tumor Environment—How to Target Them?
Cinier, J., Hubert, M., Besson, L., Roio, A. D., Rodriguez, C., Lombardi, V., Caux, C., & Ménétrier‐Caux, C. (2021) · Cancers · doi:10.3390/cancers13081850 · Cited by 125
Roles of TGF-β signaling pathway in tumor microenvirionment and cancer therapy
Zhao, H., Wei, J., & Sun, J. M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107101 · Cited by 118
Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
Husain, B., & Ellerman, D. A. (2018) · BioDrugs · doi:10.1007/s40259-018-0299-9 · Cited by 116
Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy
Ahern, E. S., Smyth, M. J., Dougall, W. C., & Teng, M. W. L. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0095-y · Cited by 115
Tumor metastasis: Mechanistic insights and therapeutic interventions
Liu, M., Yang, J., Xu, B.-S., & Zhang, X. (2021) · MedComm · doi:10.1002/mco2.100 · Cited by 124
Radioimmunotherapy for the treatment of head and neck cancer
Karam, S. D., & Raben, D. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30306-7 · Cited by 104
Recent developments with immunotherapy for hepatocellular carcinoma
Waidmann, O. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1499722 · Cited by 103
Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics
Zhang, J., Hu, Z., Horta, C. A., & Yang, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.002 · Cited by 106
Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy
Liu, L., Huang, X., Shi, F., Song, J., Guo, C., Yang, J., Liang, T., & Bai, X. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02273-w · Cited by 105
Biology drives the discovery of bispecific antibodies as innovative therapeutics
Nie, S., Wang, Z., Moscoso‐Castro, M., D'Souza, P., Lei, C., Xu, J., & Gu, J. (2020) · Antibody Therapeutics · doi:10.1093/abt/tbaa003 · Cited by 97
TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
Yi, M., Li, T., Niu, M., Wu, Y., Zhao, Z., & Wu, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1061394 · Cited by 95
Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations
Colton, M., Cheadle, E. J., Honeychurch, J., & Illidge, T. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01678-1 · Cited by 97
Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities
Bauer, A. T., Gorzelanny, C., Gebhardt, C., Pantel, K., & Schneider, S. W. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102322 · Cited by 94
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
Cho, B. C., Daste, A., Ravaud, A., Salas, S., Isambert, N., McClay, E. F., Awada, A. H., Borel, C., Ojalvo, L. S., Helwig, C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000664 · Cited by 93
Self-citation
TGFβ-Directed Therapeutics: 2020
Teicher, B. A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107666 · Cited by 96
Transforming growth factor β signaling pathway: A promising therapeutic target for cancer
Chen, Y., Di, C., Zhang, X., Wang, J., Wang, F., Yan, J., Xu, C., Zhang, J., Zhang, Q., Li, H., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29108 · Cited by 89
Identification of a Tumor Microenvironment-relevant Gene set-based Prognostic Signature and Related Therapy Targets in Gastric Cancer
Cai, W., Dong, Z.-N., Fu, X.-T., Lin, L., Wang, L., Ye, G.-D., Luo, Q., & Chen, Y. (2020) · Theranostics · doi:10.7150/thno.47938 · Cited by 89
Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity
Horn, L. A., Riskin, J., Hempel, H., Fousek, K., Lind, H., Hamilton, D. H., McCampbell, K. K., Maeda, D. Y., Zebala, J. A., Su, Z., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000326 · Cited by 90
Self-citation
Trials and tribulations of pancreatic cancer immunotherapy
Principe, D. R., Korc, M., Kamath, S. D., Munshi, H. G., & Rana, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.01.031 · Cited by 95
Using human genetics to improve safety assessment of therapeutics
Carss, K., Deaton, A. M., Río-Espínola, A. D., Diogo, D., Fielden, M. R., Kulkarni, D. A., Moggs, J. G., Newham, P., Nelson, M. R., Sistare, F. D., et al. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00561-w · Cited by 90
TGFβ Signaling in the Pancreatic Tumor Microenvironment
Principe, D. R., Timbers, K. E., Atia, L. G., Koch, R. M., & Rana, A. (2021) · Cancers · doi:10.3390/cancers13205086 · Cited by 85
Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma
Gautam, S. K., Batra, S. K., & Jain, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01813-y · Cited by 93
Tumor microenvironment and immunotherapy for triple-negative breast cancer
Guo, Z., Zhu, Z., Lin, X., Wang, S., Wen, Y., Wang, L., Zhi, L., & Zhou, J. (2024) · Biomarker Research · doi:10.1186/s40364-024-00714-6 · Cited by 95
Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines
Okusaka, T., & Furuse, J. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01666-y · Cited by 88
Facts and Hopes in Immunotherapy of Pancreatic Cancer
Bockorny, B., Grossman, J. E., & Hidalgo, M. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3452 · Cited by 87
The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial
Metropulos, A. E., Munshi, H. G., & Principe, D. R. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104380 · Cited by 81
Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
Rumfield, C. S., Pellom, S. T., Morillon, Y. M., Schlom, J., & Jochéms, C. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000612 · Cited by 83
Self-citation
The state of the art of bispecific antibodies for treating human malignancies
Wang, S., Chen, K., Lei, Q., Ma, P., Yuan, A. Q., Zhao, Y. J., Jiang, Y., Hong, F., Xing, S., Fang, Y., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114291 · Cited by 85
Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights
Ni, J., Zhang, Z., Ge, M.-J., Chen, J., & Zhuo, W. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00953-z · Cited by 85
Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial
Liu, D., Zhou, J., Wang, Y., Li, M., Jiang, H., Liu, Y., Yin, X., Ge, M., Xiang, X., Ying, J., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02605-9 · Cited by 86
The strategies to cure cancer patients by eradicating cancer stem-like cells
Mai, Y., Su, J., Yang, C., Xia, C., & Fu, L. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01867-y · Cited by 78
Therapeutic strategies to remodel immunologically cold tumors
Wang, M., Wang, S., Desai, J., Trapani, J. A., & Neeson, P. J. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1226 · Cited by 79
Anti‐PD‐L1/TGF‐βR fusion protein (SHR‐1701) overcomes disrupted lymphocyte recovery‐induced resistance to PD‐1/PD‐L1 inhibitors in lung cancer
Cheng, B., Ding, K., Chen, P., Ji, J., Luo, T., Guo, X., Qiu, W., Ma, C., Meng, X., Wang, J., et al. (2022) · 癌症：英文版 · doi:10.1002/cac2.12244 · Cited by 76
Immune checkpoint inhibitors in colorectal cancer: limitation and challenges
Yan, S., Wang, W., Feng, Z., Xue, J., Liang, W., Wu, X., Tan, Z., Zhang, X., Zhang, S., Li, X., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1403533 · Cited by 83
Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression
van den Bulk, J., de Miranda, N. F. C. C., & ten Dijke, P. (2021) · Clinical Science · doi:10.1042/cs20201236 · Cited by 78
Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy
Collins, J. M., Redman, J. M., & Gulley, J. L. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1506332 · Cited by 73
Self-citation
The roles of TGF-β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors
Bu, M. T., Chandrasekhar, P., Ding, L., & Hugo, W. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108211 · Cited by 72
Advances in Diagnosis and Therapy for Bladder Cancer
Hu, X., Li, G., & Wu, S. (2022) · Cancers · doi:10.3390/cancers14133181 · Cited by 77

Authors: Strauss, J., Heery, C. R., Schlom, J., Madan, R. A., Cao, L., Kang, Z., Lamping, E., Marté, J. L., Donahue, R. N., Grenga, I., Cordes, L., Christensen, O., Mahnke, L., Helwig, C., & Gulley, J. L.
Affiliations: National Institutes of Health (US)
7EMD Serono, Billerica, Massachusetts.
Merck KGaA, Darmstadt (Germany) (DE)
Corresponding author: Gulley, James L.
ORCID: Strauss, Julius
Schlom, Jeffrey
Madan, Ravi A.
Cao, Liang
Kang, Zhigang
Marté, Jennifer L.
Donahue, Renee N.
Cordes, Lisa
Helwig, Christoph
Gulley, James L.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2018-03-14
Volume: 24
Issue: 6
Pages: 1287-1295
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-17-2653
PMC: PMC7985967
OpenAlex: W2781947653
Cited by: 406
References: 35
Citations by year: 2026: 22 · 2025: 29 · 2024: 48 · 2023: 40 · 2022: 81 · 2021: 73 · 2020: 64 · 2019: 26 · 2018: 20
FWCI: 17.20
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (HHSN261200800001C)
National Cancer Institute (HHSN261200800001E), ZIABC010945)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: bifunctional fusion protein, PD-L1, TGF-β trap, TGF-β1, TGF-beta2, TGF-beta3, advanced solid tumors, maximum tolerated dose, safety, pharmacokinetics, immunogenicity, cervical cancer, pancreatic cancer, anal cancer, carcinoid tumor, dose escalation
MeSH terms: Antineoplastic Agents, Immunological, Adult, Aged, Combined Modality Therapy, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Neoplasms, Transforming Growth Factor beta, Treatment Outcome, Antibodies, Bispecific, Retreatment, Molecular Targeted Therapy, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks